Agenus Inc (NASDAQ:AGEN)
| Market Cap | $310.84M+55.1% |
| Revenue (ttm) | $133.95M+25.4% |
| Net Income | $30.83M+187.7% |
| EPS | $0.73+132.5% |
| Shares Out | 45.25M |
| PE Ratio | 9.34 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 498,928 |
| Open | $7.07 |
| Previous Close | $7.22 |
| Day's Range | $6.78 - $7.08 |
| 52-Week Range | $2.71 - $10.31 |
| Beta | 1.52 |
| Analysts | Buy |
| Price Target | $25.00(+263.90%) |
| Earnings Date | Mar 15, 2027 |
About AGEN
Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 antibody currently undergoing Phase 1/2 clinical evaluation. AGEN2373: An anti-CD137 monospecific antibody in Phase 1 clinical trials. AGEN1423: A bi-functional anti-CD73/TGFß TRAP antibody, engineered to modulate the tumor microenvironment, which has concluded Phase 1 studies. AGEN1777: An anti-TIGIT bispecific antibody. AGEN1327: A human monoclonal antibody. INCAGN1876: An anti-GITR monospecific antibody. INCAGN1949: An anti-OX40 monospecific antibody. INCAGN2390: An anti-TIM-3 monospecific antibody. INCAGN2385: An anti-LAG-3 monospecific antibody. MK-4830: A monospecific antibody engineered to target ILT4. AGENT 797: An iNKT cell therapy, currently in Phase 1 for solid tumors, multiple myeloma, and viral ARDS, with ongoing clinical investigation for hematological malignancies and multiple myeloma/B cell indications. AGEN1884: A first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. utilizes a portfolio of trademarks, including ASV, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon, alongside its own company name. Strategic alliances are maintained with partners such as Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Established in 1994, the company originally operated as Antigenics Inc. before rebranding to Agenus Inc. in January 2011. Its corporate headquarters are situated in Lexington, Massachusetts.
Analyst consensus
2 firms rating AGEN in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 15, 2027Earnings report
$AGEN stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in AGEN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by AGEN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
AGEN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
AGEN Revenue by Segment or Geography
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New AGEN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to AGEN from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in AGEN
| VTIVanguard Morningstar Total Stock Market ETF | $12.49M |
| IWMiShares Russell 2000 ETF | $7.10M |
| VXFVanguard Extended Market ETF | $3.96M |
| IWNiShares Russell 2000 Value ETF | $2.27M |
| VTWOVanguard Russell 2000 ETF | $2.21M |
| FDMFirst Trust Dow Jones Select MicroCap Index Fund | $1.11M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from AGEN’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q3 earnings matched expectations with revenue miss, but offset by clinical trial progress and first marketing authorizations for BOT+BAL treatment.